Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Cullgen ditches reverse merger with Pulmatrix to go with Gyre in $300M buyout

Cullgen ditches reverse merger with Pulmatrix to go with Gyre in $300M buyout

  • March 2, 2026

More than a year after first agreeing to a reverse merger with Pulmatrix, protein degradation biotech Cullgen has instead opted to be bought by Gyre Therapeutics in a $300 million all-stock acquisition.

Leave A Comment

Fields (*) Mark are Required